Blackstone Puts $455M Behind Boston Scientific's VITALYST Heart Pump
BSX is trading near its 52-week low of $39.57 (12% above the low).
Summary
Blackstone Life Sciences committed $455 million to co-fund development of Boston Scientific's VITALYST temporary heart pump, a miniature circulatory support device aimed at acute myocardial infarction cardiogenic shock. It's the first time the two have co-funded a Boston Scientific product, so Blackstone is taking on a chunk of the development cost and risk for a program still in development. The money is modest next to Boston Scientific's scale, but it validates the VITALYST program and offloads spend on a device that won't contribute revenue for some time. This lands days after the Q3 10-Q confirmed the cyberattack cut gross margin to 66.7% and after Q4 guidance came in below consensus, so it's a rare piece of good news in a rough stretch. No approval timeline or financial terms beyond the $455 million were disclosed.
At the time of this announcement, BSX was trading at $44.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $64.2B. The 52-week trading range was $39.57 to $105.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.